Some links on this site are affiliate links. If you purchase through them, we may earn a small commission at no extra cost to you. We only recommend products we believe in.
I'm not a cannabis evangelist. But when I read the actual trial data, the effect size for neuropathic pain is roughly comparable to gabapentin, with a different side-effect profile. For men running out of options, that's worth a specialist conversation, not a moral panic.
The clinical evidence for cannabis in chronic pain is better than many sceptics acknowledge and less definitive than advocates claim. Here's an evidence-based assessment of what the research actually shows, where the gaps are, and what it means for men with persistent pain who haven't found adequate relief through conventional treatments.
The Evidence Landscape
Chronic pain research on cannabinoids is complex for several reasons:
Regulatory barriers: Cannabis research has been severely restricted historically by Schedule 1 classification in the US and equivalent restrictions internationally. The evidence base is thinner than it would be for a compound with this much clinical interest in any other category.
Heterogeneous interventions: Different cannabinoid ratios (THC:CBD), different routes of administration, different patient populations, different pain types. Meta-analyses are comparing partially different interventions, which creates noise.
Subjective endpoint: Pain is measured by self-report. This makes trial design (adequate blinding particularly) more challenging for cannabis than for conditions with objective biomarkers.
Despite these limitations, the evidence is meaningful.
What Systematic Reviews Conclude
The 2022 Cochrane review - the most authoritative systematic review series in medicine - analysed 32 randomised controlled trials involving cannabinoids for chronic neuropathic pain. Findings: moderate-certainty evidence that cannabis-based medicines are more effective than placebo at reducing pain intensity, improving sleep quality, and improving patient global impression of change. The number needed to treat (NNT) for a 30% reduction in pain was approximately 11, compared to NNT of 6–8 for standard neuropathic pain medications (gabapentin, amitriptyline). Cannabinoids are not more effective than existing first-line treatments; they appear roughly comparable in effect size.
A 2022 BMJ systematic review analysed 32 RCTs of medical cannabis for chronic non-cancer pain. Conclusion: moderate evidence for clinically meaningful pain reduction, sleep improvement, and improved quality of life, primarily in neuropathic pain. Evidence weaker for non-neuropathic musculoskeletal or inflammatory pain.
A 2019 review in the Journal of the American Medical Association looked at chronic pain specifically and found similar conclusions: cannabis-based medicines produce modest but statistically significant pain reduction compared to placebo, with improvements in sleep as a consistent secondary finding.
Types of Pain and Evidence Quality
Neuropathic pain (nerve damage, diabetic neuropathy, post-herpetic neuralgia): Best evidence. Multiple positive RCTs. This is where UK specialist clinics focus most prescribing.
MS-related pain and spasticity: Strong evidence. Sativex (THC:CBD) is licensed in the UK specifically for this.
Cancer-related pain: Evidence primarily from small RCTs; mostly positive signal for pain and nausea.
Fibromyalgia: Limited but positive evidence from small trials. Not yet a primary indication in UK clinical guidelines.
Musculoskeletal pain (back pain, joint pain): Weakest evidence for cannabinoids specifically. More evidence for anti-inflammatory effects of CBD but less RCT data on medical cannabis products for this category.
The Comparison With Opioids
This is where medical cannabis prescribing has a significant public health argument behind it. Chronic opioid therapy for non-cancer pain is associated with tolerance, dependence, hyperalgesia (paradoxically increased pain sensitivity), hormonal suppression, and significant overdose risk.
Multiple observational studies have found that access to medical cannabis is associated with reduced opioid prescribing and opioid-related hospitalisation. A 2019 study in JAMA Internal Medicine found that states with medical cannabis laws had significantly lower rates of opioid mortality.
For men on long-term opioid therapy for chronic pain who are experiencing diminishing returns, tolerance, or significant side effects, medical cannabis as a partial or complete opioid substitute is a legitimate clinical discussion - not an alternative medicine fringe position.
Side Effects and Risks
The research is reasonably clear on the side effect profile:
Acute effects (THC): Cognitive impairment, impaired driving ability, tachycardia, anxiety in some users (particularly at higher doses or in those with anxiety predisposition), dry mouth. These are dose-dependent and manageable through appropriate dosing and titration.
Chronic effects: Regular THC use is associated with cognitive effects in heavy users. Medical cannabis at therapeutic doses with clinical monitoring appears to carry lower risk than recreational heavy use, but the evidence on long-term cognitive effects at medical doses is not yet fully characterised.
Cannabis use disorder: Approximately 9% of cannabis users develop dependence - lower than alcohol (~15%), tobacco (~32%), and opioids (~23%), but real. Physical dependence on THC can develop. Medically monitored prescribing reduces but doesn't eliminate this risk.
Cardiovascular: Acute cannabis use transiently increases heart rate and blood pressure. Men with significant cardiovascular disease need careful clinical assessment before prescribing.
Hormonal (testosterone): As noted elsewhere, heavy chronic THC use suppresses LH and testosterone. At medical doses with appropriate monitoring, the clinical significance for most men is manageable, but monitoring testosterone is appropriate for men on ongoing THC-dominant prescriptions.
The Right Clinical Context
Medical cannabis via a specialist clinic like Releaf is appropriate in specific circumstances: diagnosed chronic pain condition, documented inadequate response to conventional treatments, appropriate patient selection (absence of contraindications), ongoing monitoring. In this context, the evidence supports it as a meaningful addition to the chronic pain management toolkit.
It is not a lifestyle supplement. It is not an alternative to conventional first-line treatment. It is a legitimate option for a specific patient population where conventional approaches have failed.
The evidence for medical cannabis in chronic neuropathic pain is moderate but real, with effect sizes broadly similar to gabapentinoids. It belongs in specialist hands, after first-line treatments, with ongoing monitoring of cognition, cardiovascular markers and testosterone.
This article reviews published research and does not constitute medical advice. Medical cannabis is a prescription-only medicine in the UK. Consult a specialist for personal medical guidance.
